STOCKHOLM/UMEÅ. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel GABAA receptor modulator for the treatment of CNS-related disorders, today announces that Dr. Eva Arlander has been appointed as Chief Development Officer.
Dr. Eva Arlander brings more than 25 years of experience in the pharmaceutical and biotechnology sectors, where she has held senior positions at AstraZeneca, Medivir and Affibody. She joins Umecrine Cognition from a role as Director, Department of Pharmaceuticals in use at the Swedish Medical Products Agency (Läkemedelsverket). Her extensive knowledge of clinical drug development, regulatory affairs and commercial strategies for pharmaceutical products will be instrumental in Umecrine Cognition’s continued efforts to create value to patients and shareholders based on its unique drug candidate GR3027.
Magnus Doverskog, CEO of Umecrine Cognition, said: “We are pleased to welcome Eva Arlander to the company. She has a unique blend of knowledge and experience from designing and leading clinical trials, interactions with regulatory bodies and commercialization of innovative pharmaceutical products.”
Eva Arlander, incoming Chief Development Officer, commented: “I am looking forward to contribute in Umecrine Cognition’s efforts to bring forward entirely new treatments for a range of underserved CNS-related disorders, such as hepatic encephalopathy and idiopathic hypersomnia.”
Dr. Arlander holds a Ph.D. in Medical Sciences from the Karolinska Institute and a M.Sc. in Pharmacy from Uppsala University. She has held positions as Vice President R&D at Affibody Holding AB, Vice President Commercial, Project Director Clinical Development and Director Clinical Research at Medivir AB, Project Leader and Line Manager Clinical R&D at AstraZeneca AB, and Clinical Research Manager at Astra Pain Control. Since 2013, she has held a role as Director at the Swedish Medical Products Agency, heading a group of 30 employees involved in the improvement of pharmaceutical use. In this capacity, she has been responsible for e.g. development of treatment guidelines, the MPA’s first e-health strategy and ten government commissions.
Eva Arlander will take on her position as Chief Development Officer immediately.
For further information, please contact:
Magnus Doverskog, PhD, MBA, CEO, Umecrine Cognition AB.
Phone: +46 (0)73 039 20 52, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Umecrine Cognition AB
Umecrine Cognition, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, is developing its drug candidate GR3027 as a new target class therapy relevant for several major CNS-related disorders. The primary focus is to develop a treatment for life-threatening overt hepatic encephalopathy and long-term treatment in covert hepatic encephalopathy in patients with liver disease, a growing area with high unmet medical need. The current lack of therapeutics that directly addresses the neurocognitive signs and symptoms of Hepatic Encephalopathy makes a novel treatment likely to become a major contribution for the treatment of this disorder. Further, the company is pursuing clinical development of its drug candidate in patients with Idiopathic Hypersomnia – a potentially debilitating orphan disease characterized by chronic excessive daytime sleepiness despite normal sleep. For more information, please visit www.umecrinecognition.com.